Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKesson
Daiichi Sankyo
US Army
Queensland Health
Colorcon
Novartis
Harvard Business School
Fuji
Federal Trade Commission

Generated: December 12, 2017

DrugPatentWatch Database Preview

Mannkind Company Profile

« Back to Dashboard

What is the competitive landscape for MANNKIND, and when can generic versions of MANNKIND drugs launch?

MANNKIND has one approved drug.

There are thirty-five US patents protecting MANNKIND drugs.

There are three hundred and ninety-nine patent family members on MANNKIND drugs in twenty-six countries and forty-two supplementary protection certificates in twelve countries.

Summary for Mannkind

International Patents:399
US Patents:35
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Mannkind

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014► Subscribe► Subscribe
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Mannkind

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,799,344Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents► Subscribe
9,006,175Potentiation of glucose elimination► Subscribe
8,372,804Delivery of active agents► Subscribe
8,420,604Method of drug formulation of compositions comprising crystalline microparticle surfaces► Subscribe
9,066,881Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces► Subscribe
9,089,497Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces► Subscribe
8,377,869Method of preventing adverse effects by GLP-1► Subscribe
8,671,937Unit dose capsules and dry powder inhaler► Subscribe
9,078,866Method for treating hyperglycemia with GLP-1► Subscribe
8,921,311Method for treating hyperglycemia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Mannkind Drugs

Country Document Number Estimated Expiration
European Patent Office2010155► Subscribe
China201643274► Subscribe
India9128DEN2014► Subscribe
Japan2011524210► Subscribe
Hong Kong1117768► Subscribe
South Korea20150143894► Subscribe
Mexico340112► Subscribe
Japan5898156► Subscribe
Argentina104035► Subscribe
European Patent Office2364717► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Mannkind Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
C0035France► SubscribePRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121
90067-4Sweden► SubscribePRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
60026Netherlands► SubscribePRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
2107069/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC; REGISTRATION NO/DATE: SWISSMEDIC 62563 12.03.2013
C0009France► SubscribePRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
13/34Ireland► SubscribePRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
C0044Belgium► SubscribePRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
2107069/02Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013
91022-0Sweden► SubscribePRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Deloitte
Daiichi Sankyo
McKesson
Mallinckrodt
Moodys
Farmers Insurance
Cerilliant
Argus Health
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot